EL: Annual Thesis 2025–2026
FY25 (Jun 2025 FYE) revenue $14.29B (-8%); Op income $958M (-1%); Net loss -$1.13B; EPS -$3.15. Gross margin expanded 230bp to 74%. China + travel retail still ~15% of sales (down from prior years). FY26 mgmt guide low-single-digit organic growth and +165bp op margin expansion.
Key takeaways
- The reset is now four years long. Revenue stepped down from $17.7B FY22 → $15.9B FY23 → $15.6B FY24 → $14.3B FY25. EPS fell from $6.55 → $2.79 → $1.08 → -$3.15. The FY25 GAAP loss embeds further restructuring + impairment charges; underlying operating income is $958M, not negative.
- Travel retail collapse is the largest single driver. Travel retail revenue down 28% YoY in FY25 and now ~15% of reported sales (down 4pp from FY24). Roughly two-thirds of FY25's 8% organic decline came from travel retail alone. Trade inventory now described as "healthier."
- Gross margin actually expanded. GM 74% in FY25, +230bp YoY — the supply chain optimization and SKU rationalization under PRGP (Profit Recovery and Growth Plan) is showing up. Operating margin compressed because SG&A didn't fall fast enough as revenue declined.
- The PRGP playbook is working in pockets. Share gains in China prestige beauty (La Mer, Estée Lauder), Japan, and US. Online sales reached 31% of reported (up from prior years). The Ordinary growing high-single-digit retail sales in Q4. La Mer + Estée Lauder driving share in China.
- FY26 guide is the inflection signal. Mgmt guide: low-single-digit organic sales growth, gross margin held despite incremental tariffs, operating margin +165bp at midpoint. Significantly reduce discounting, accelerate consumer coverage, lean into emerging markets. AI-powered Tmall flagship for The Ordinary launched Q1 FY26.
Business
Estée Lauder is a prestige beauty pure-play across four product categories and four regions. Brand portfolio: Estée Lauder, Clinique, M·A·C, La Mer, Bobbi Brown, Jo Malone London, Tom Ford Beauty (license), Origins, Aveda, Dr. Jart+, The Ordinary (DECIEM), Bumble and bumble, Smashbox, GLAMGLOW, and others.
- Skin Care: ~50% of sales. La Mer + Clinique + Estée Lauder Re-Nutriv + Origins + Dr. Jart+. Highest gross margin category. La Mer drove FY25 China share gains.
- Makeup: ~30%. M·A·C + Bobbi Brown + Smashbox + Tom Ford Beauty + GLAMGLOW. Most exposed to travel retail destocking.
- Fragrance: ~15%. Jo Malone London + Tom Ford + Le Labo. Premium-mix held up better than rest of portfolio.
- Hair Care: ~5%. Aveda + Bumble and bumble.
Geographic mix:
- Americas ~30% (US/Canada/LatAm)
- EMEA ~40% (incl. travel retail historically clustered here, now in restructuring)
- Asia/Pacific ~30% (China the swing factor)
Travel retail (cross-border duty-free at airports + cruise + Hainan offshore duty-free) historically peaked at ~25% of revenue. Now ~15% after multi-year normalization of Asian outbound travel pricing arbitrage and Chinese policy on daigou.
The Ordinary (DECIEM) is the high-growth subplot — masstige skincare with viral TikTok-era brand recognition, growing high-single-digit in Q4 FY25 with newly launched AI-powered Tmall flagship.
FY25 financial performance
| Metric (FY, June FYE) | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue ($B) | 17.74 | 15.91 | 15.61 | 14.29 |
| Gross profit ($B) | 13.43 | 11.35 | 11.18 | 10.56 |
| Gross margin | 75.7% | 71.3% | 71.6% | 73.9% |
| Op income ($M) | 3,170 | 1,509 | 970 | 958 |
| Op margin | 17.9% | 9.5% | 6.2% | 6.7% |
| EBITDA ($M) | 3,930 | 2,396 | 1,975 | 193 |
| Net income ($M) | 2,390 | 1,006 | 390 | -1,133 |
| Diluted EPS ($) | 6.55 | 2.79 | 1.08 | -3.15 |
| FCF ($M) | 2,000 | -1,558 | 1,441 | 670 |
| Capex ($M) | -1,040 | -3,289 | -919 | -602 |
| Dividends ($M) | -840 | -925 | -947 | -618 |
| Buyback ($M) | -2,309 | -271 | -35 | -35 |
| Total debt ($B) | 7.65 | 10.17 | 9.83 | 9.44 |
Two divergences worth tracking:
- GAAP NI vs underlying OI: -$1.13B net loss vs $958M operating income → ~$2B of below-the-line charges (restructuring, impairments, tax). EBITDA collapse to $193M reflects the same charges.
- GM up 230bp while OI is flat: SKU rationalization + supply chain savings funded the GM expansion, but SG&A deleverage on lower revenue offset most of it.
The dividend was meaningfully reduced in late FY24 (from $0.66/qtr to $0.35/qtr) — full FY25 cash dividend $-618M reflects that lower run rate. Buybacks are essentially zero ($-35M) preserving balance sheet flexibility.
Capital allocation
- Capex: $-602M FY25, normalized down from the $-3.29B FY23 spike (which was Hainan / global supply chain build-out). Capital intensity down to ~4.2% of revenue.
- Dividends: $-618M FY25 on the reduced rate. The cut signals management prioritizing balance sheet repair over yield support during the reset.
- Buybacks: zero meaningful activity. Capital is conserved for restructuring + portfolio review.
- Debt: total debt held at $9.4B (vs $9.8B FY24) — small paydown despite the loss year, a credit-positive signal that the cash flow can still service the debt stack.
- Portfolio review: management announced in FY25 it is engaging external advisers to review the full brand portfolio "to align with Beauty Reimagined" — divestiture of underperforming brands is on the table in FY26.
FY26 outlook (per Q4 FY25 earnings call, 2025-08-20)
| FY26 guide | Range / target |
|---|---|
| Organic revenue growth | Low single-digit (+1% to +3%) |
| Gross margin | Maintain FY25 level (~74%) despite tariffs |
| Operating margin | +165bp at midpoint vs FY25 |
| Discounts | Significantly reduce |
| Geographic emphasis | High-growth emerging markets (incremental) |
| Restructuring | PRGP execution continues |
The +165bp operating margin expansion target is the headline number to track. Bridge: lower discounting (gross margin support) + SG&A leverage on stable+ revenue + PRGP cost-out − incremental tariff drag = +165bp midpoint. Hitting this implies operating income ~$1.2-1.3B FY26 (vs $958M FY25).
Worth noting: Q1 FY26 launches highlighted by management — The Ordinary AI-powered Tmall flagship, expanded EM emphasis. Watch for travel retail stabilization and China prestige market growth as the leading indicators.
Key risks
- China demand: Prestige beauty in China remains the single biggest swing factor. Hainan duty-free policy, Chinese consumer confidence, and competitive intensity (local prestige brands + L'Oréal Asia execution) all material.
- Travel retail: Stabilizing per management commentary, but a renewed disruption (currency, daigou crackdown, regional travel pullback) would compress 15% of sales further.
- Tariff impact: FY26 guide explicitly bakes incremental tariffs but management aims to offset via pricing + supply chain. Margin slip is the risk if mitigation doesn't keep pace.
- Brand portfolio review: Divestitures may produce one-time gains but could compress reported revenue/EBITDA going forward; valuation methodology matters.
- Promotional environment: "Significantly reduce discounts" guide assumes the prestige beauty market doesn't escalate promotional intensity. If competition escalates, GM expansion thesis breaks.
- Capital structure: $9.4B debt against now-reduced earnings power. Coverage ratios are below historical norms; another revenue down-leg would test covenants.
Bottom line
EL FY25 is the third consecutive reset year, but the gross margin expansion + portfolio review + dividend reset suggest the reset playbook is in late innings rather than mid-game. The thesis going into FY26 is whether the +165bp operating margin guide is hittable — if it is, FY26 OI of $1.2-1.3B implies real recovery off the trough. If China + travel retail continue to disappoint, the bear case is another year of revenue stagnation with margin progress masked by FX or tariff drag.
Two things to watch each quarter: (1) travel retail trend (+/-, vs 28% decline base), (2) China prestige share — both have to inflect for the thesis to work.
Citations
- Estée Lauder FY25 Form 10-K, filed late August 2025 (SEC EDGAR; June 30, 2025 fiscal year end).
- Estée Lauder Q4 FY25 earnings call, 2025-08-20 — segment commentary, FY26 guide, portfolio review, La Mer/Ordinary detail.
- Estée Lauder PRGP (Profit Recovery and Growth Plan) updates within Q1–Q3 FY25 calls.
- Internal financial_statements view (consolidated annual + cash flow).